Compound antiarrhythmic

Abstract

The invention relates to a compound anti-arrhythmic drug which is composed of a calcium antagonist verapamil or diltiazem and digitalis drug. The positive inotropic effect of the digitalis drug can resist the negative inotropic effect of the verapamil or the diltiazem, while the effect of delaying the atrioventricular conduction thereof can strengthen the treatment effect of delaying the atrioventricular conduction of the verapamil or the diltiazem. In the compound drug, the used dose of the verapamil or the diltiazem is reduced, thus increasing safety and expanding scope of application.

Description

technical field [0001] The invention relates to the technical field of medicine, and is a compound antiarrhythmic drug. technical background [0002] Calcium antagonists verapamil and diltiazem are currently commonly used drugs for the treatment of paroxysmal supraventricular tachycardia, atrial fibrillation, and atrial flutter. Both of these two drugs have a common disadvantage, that is, they both have a supplementary inotropic effect, so when used by some patients, they will cause deterioration of cardiac function and threaten the safety of patients. This shortcoming also limits the application of these two drugs in patients with poor cardiac function. Contents of the invention [0003] The mechanism of calcium antagonists verapamil and diltiazem in the treatment of paroxysmal supraventricular tachycardia, atrial fibrillation, and atrial flutter lies in the pharmacological effects of these two drugs to delay atrioventricular conduction. Both of these two drugs have a c...

AI Technical Summary

Problems solved by technology

Both of these two drugs have a common disadvantage, that is, they both have an inotropic effect, so when used by some patients, they will cause deterioratio